Clinical Trial Update: Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation [Phase 2]

View source ↗

Summary

Phase 2 trial updating alternating icotinib and chemotherapy for advanced non-small cell lung cancer with EGFR mutation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• icotinib (icotinib)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Lung Adenocarcinoma | Phase 2 | Status: UNKNOWN